Drugs that are agonists of the receptor PPAR-gamma are used to treat individuals with diabetes. However, it has been suggested that their use is associated with a slightly increased risk of heart failure. In a new study, Ira Goldberg and colleagues at Columbia University, New York, outline a potential explanation for the adverse effects observed in a minority of patients being treated with PPAR-gamma agonists.
